Design Principles of Intelligent Personalized Healthcare Systems

Daniil Salnikov
Belarusian State University of Informatics and Radioelectronics
Minsk, Belarus
d.salnikov@bsuir.by

***Abstract*—this article proposes an approach for designing next-generation intelligent personalized healthcare systems, emphasizing the synergy between technological innovation and clinical applicability. The study delineates architectural frameworks, knowledge integration methodologies, ethical governance models, and human-intelligent system interaction paradigms essential for developing scalable, secure, and socially acceptable solutions. By analyzing interdisciplinary approaches spanning computer science, clinical medicine, and bioethics, the research aims to bridge the gap between theoretical advancements and real-world clinical integration, ensuring that such systems align with both technical feasibility and patient-centered care imperatives.**

***Keywords*—intelligent personalized healthcare systems, semantic interoperability, artificial intelligence in healthcare, patient-centric care, predictive analytics, ethical governance, health data security, explainable AI, chronic disease management, regulatory compliance, 4P medicine (predictive, preventive, personalized, participatory), OSTIS, blood-based biomarkers, algorithmic bias mitigation.**

I. Introduction

The contemporary healthcare landscape is undergoing a paradigm shift driven by the escalating prevalence of chronic diseases, aging populations, and the growing demand for personalized, patient-centric care. Traditional healthcare models, predominantly reactive and episodic, face significant limitations in addressing the complexities of preventive medicine, longitudinal health monitoring, and individualized treatment strategies. Concurrently, systemic challenges such as resource scarcity, geographic disparities in access to specialists, and the rising burden on medical infrastructure underscore the urgent need for innovative solutions [1].

Intelligent personalized healthcare systems have emerged as a transformative force, leveraging advancements in artificial intelligence, machine learning, the Internet of Medical Things, and big data analytics. These systems enable a transition from fragmented care to continuous, data-driven health management, integrating real-time biosensor data, electronic health records, and multi-omics information to generate actionable insights. For instance, wearable biosensors facilitate ubiquitous monitoring of physiological parameters, while artificial intelligence-driven predictive analytics identify early biomarkers of conditions such as diabetes mellitus or cardiovascular disorders, enabling preemptive interventions.

However, the design and deployment of intelligent personalized healthcare systems entail multifaceted challenges. A critical issue lies in achieving semantic interoperability across heterogeneous data sources, including electronic health records, genomic datasets, and environmental sensors, which often adhere to disparate standards and formats. The reliability of artificial intelligence algorithms, particularly in scenarios with imbalanced or incomplete data, remains a persistent concern, necessitating robust validation frameworks to mitigate risks of diagnostic inaccuracies. Ethical and regulatory complexities, such as ensuring patient privacy under regulations like the General Data Protection Regulation and the Health Insurance Portability and Accountability Act, maintaining algorithmic transparency through explainable artificial intelligence, and addressing biases in training datasets, further complicate implementation. Additionally, adaptive learning mechanisms are required to enable systems to evolve with dynamic patient states and emerging medical knowledge without catastrophic forgetting [2].

II. Core requirements for intelligent personalized healthcare systems

The development of intelligent personalized healthcare systems demands a rigorous framework of requirements to ensure their efficacy, safety, and alignment with clinical and ethical standards. This section outlines the foundational prerequisites that guide the design and implementation of such systems, focusing on functional, operational, and socio-technical dimensions rather than specific technological implementations.

A primary requirement is the unified integration of heterogeneous data sources, spanning biometric sensors, electronic health records, genomic repositories, and environmental datasets. Systems must ensure semantic consistency across diverse formats and terminologies, enabling seamless aggregation of structured and unstructured data. This necessitates adherence to internationally recognized medical data standards and ontologies, which facilitate cross-institutional data exchange and reduce ambiguities in interpretation. For instance, aligning blood pressure measurements from wearable

devices with clinical-grade equipment requires standardized metadata annotation and temporal synchronization protocols [3].

Intelligent personalized healthcare systems must incorporate robust analytical frameworks capable of delivering precise, context-aware insights. Machine learning algorithms should demonstrate resilience to data imbalances, such as underrepresented patient demographics or rare disease cohorts, through techniques that mitigate overfitting and bias. Models must dynamically adapt to evolving patient conditions and emerging medical knowledge, avoiding performance degradation when confronted with novel data patterns. This adaptability ensures sustained relevance in clinical workflows, particularly for chronic disease management where patient states fluctuate over time [4].

To foster trust among clinicians and patients, systems must prioritize interpretability of decision-making processes. Analytical outputs, such as risk predictions or treatment recommendations, should be accompanied by human-understandable rationales that link conclusions to input data and clinical guidelines. Explainability mechanisms must clarify how variables like genetic predispositions, lifestyle factors, or historical health data influence algorithmic outcomes, ensuring alignment with evidence-based medicine principles [5].

Compliance with global data protection regulations, such as the General Data Protection Regulation and the Health Insurance Portability and Accountability Act, mandates end-to-end security architectures. Systems must implement encryption protocols for data transmission and storage, granular access controls, and audit trails to prevent unauthorized use. Privacy-preserving techniques, such as federated learning, should enable collaborative model training without centralized data pooling, minimizing exposure of sensitive patient information [6].

User-centric design is critical to ensure intuitive interaction for both patients and healthcare providers. Interfaces must accommodate varying levels of digital literacy, offering customizable dashboards, multilingual support, and adaptive feedback mechanisms. For patients with disabilities, compliance with accessibility standards—such as screen reader compatibility and voice navigation—is essential. Clinician-facing tools should integrate seamlessly into existing workflows, minimizing cognitive load through automated data synthesis and prioritized alerting systems [7].

Systems must embed ethical governance frameworks to address biases in algorithmic decision-making, ensuring equitable outcomes across diverse populations. Transparent consent mechanisms are required for data collection and secondary use, particularly for genomic or behavioral information. Regulatory compliance extends beyond data privacy to encompass clinical validation processes, wherein algorithms undergo rigorous testing against real-world cohorts to verify safety and efficacy before deployment [8], [9].

Architectures must support horizontal and vertical scalability to accommodate growing patient populations and expanding data volumes. Redundancy mechanisms, such as distributed data storage and failover protocols, ensure uninterrupted operation during infrastructure failures or cyberattacks. Systems should also adapt to resource-constrained environments, such as rural healthcare settings, without compromising core functionalities [10].

III. Ethical and legal aspects

The global deployment of intelligent personalized healthcare systems necessitates a rigorous examination of the legal, ethical, and sociotechnical challenges inherent to their integration within diverse healthcare ecosystems. This section delineates the multifaceted interplay between regulatory frameworks, ethical imperatives, and technological innovation, emphasizing the imperative for harmonized standards to ensure equitable and secure healthcare delivery.

Jurisdictional disparities in regulatory approaches underscore the complexity of governing intelligent personalized healthcare systems. The European Union's General Data Protection Regulation, enacted in 2018, establishes stringent safeguards for health data processing, mandating explicit patient consent for automated decision-making under Article 22 and prohibiting algorithmic opacity in clinical diagnostics. In contrast, the United States employs a decentralized regulatory model, wherein the Health Insurance Portability and Accountability Act governs data security, while the 21st Century Cures Act promotes interoperability through standardized application programming interfaces. This fragmented approach has precipitated regulatory gaps, particularly in addressing liability for artificial intelligence-driven diagnostic errors, a void partially filled by state-level initiatives such as California's Consumer Privacy Act [11], [12].

Asian regulatory frameworks reflect divergent priorities. China's Personal Information Protection Law, implemented in 2021, emphasizes state access to health data for public health surveillance, while Japan's Act on the Protection of Personal Information prioritizes anonymization techniques to facilitate secondary data use for biomedical research. These regional incongruities complicate the development of transnational intelligent personal healthcare systems, necessitating adaptive architectures capable of complying with conflicting legal requirements [13].

A paramount ethical consideration within global healthcare ecosystems pertains to the transparency of artificial intelligence-driven decision-making processes. The World Health Organization's 2021 guidelines on

ethics and governance of artificial intelligence for health advocate for explainable artificial intelligence frameworks to ensure algorithmic outputs are interpretable by clinicians and patients. For instance, the European Commission's proposed Artificial Intelligence Act classifies intelligent personalized healthcare systems as high-risk applications, requiring exhaustive documentation of training datasets, bias mitigation strategies, and performance metrics across diverse demographic cohorts [14].

Algorithmic bias, perpetuated by non-representative training data, remains a pervasive challenge. Studies in dermatology reveal diagnostic inaccuracies in artificial intelligence models trained predominantly on lighter skin tones, disproportionately affecting populations in Sub-Saharan Africa and South Asia. Similarly, gender disparities in cardiovascular risk prediction algorithms, documented across Latin American clinical trials, underscore the global ramifications of biased model design. The African Union's Framework on Artificial Intelligence Ethics addresses these inequities by mandating inclusive dataset curation and participatory design methodologies involving underrepresented communities [15].

The absence of harmonized international standards for health data exchange poses significant barriers to the scalability of intelligent personalized healthcare systems. While the International Organization for Standardization's technical specification ISO/TS 22220 provides guidelines for patient identification, legal conflicts persist between data sovereignty laws and cloud-based system architectures. The European Union's General Data Protection Regulation restricts cross-border data transfers to jurisdictions lacking adequacy agreements, a provision incompatible with decentralized systems reliant on global server networks.

Initiatives such as the Global Digital Health Partnership, comprising 30 member states, seek to reconcile these disparities through policy alignment on data sharing and artificial intelligence governance. However, divergent national priorities—such as India's emphasis on cost-effective solutions versus Germany's focus on precision medicine—hinder consensus. Emerging technical solutions, including federated learning architectures and blockchain-based audit trails, offer partial mitigation by enabling collaborative model training without centralized data aggregation, thereby preserving jurisdictional compliance.

The World Health Organization's SMART Guidelines initiative exemplifies successful transnational cooperation, providing modular architectures for digital health systems adaptable to local epidemiological and infrastructural contexts. In Rwanda, the integration of these guidelines with intelligent personalized healthcare systems facilitated real-time prediction of malaria outbreaks while adhering to national data sovereignty laws. Conversely, the European Health Data Space, proposed in 2022, aims to unify access to electronic health records across European Union member states, though implementation challenges persist due to heterogeneous technical infrastructures and multilingual interoperability barriers.

The Global Alliance for Genomics and Health further illustrates the potential of international collaboration through its Beacon Project, which enables secure querying of genomic datasets across borders without transferring raw data. This framework balances scientific progress with ethical imperatives, ensuring compliance with regional privacy regulations such as the United States' Genetic Information Nondiscrimination Act and the European Union's General Data Protection Regulation [16].

The 2021 UNESCO Recommendation on the Ethics of Artificial Intelligence advocates for human rights-centric design principles in intelligent personalized healthcare systems, emphasizing equity, sustainability, and accountability. Parallel efforts by industry consortia, such as the Toronto Declaration on Machine Learning in Healthcare, promote open-source model sharing and third-party algorithmic audits to enhance transparency [17].

Regulatory bodies are increasingly classifying advanced intelligent personal healthcare systems as medical devices, subjecting them to premarket validation protocols. The United Kingdom's Medicines and Healthcare products Regulatory Agency, for instance, has proposed stringent evaluation criteria for artificial intelligence-driven diagnostic tools, a model adopted by Health Canada and Australia's Therapeutic Goods Administration. These developments signal a global shift toward risk-based regulation, though disparities in enforcement capacity between high-income and low-income nations threaten to exacerbate existing healthcare inequities [18].

IV. Proposed approach

In light of the identified requirements for intelligent personalized healthcare systems, including interoperability, semantic consistency, and adaptive knowledge processing, the Open Semantic Technology for Intelligent Systems (OSTIS) is proposed as a foundational framework for system design. OSTIS represents a next-generation semantic technology paradigm centered on the unified representation and context-aware processing of knowledge. Unlike conventional approaches reliant on syntactic data structures, OSTIS prioritizes semantic harmonization, enabling the integration of heterogeneous medical data, domain-specific ontologies, and decision-making algorithms into a cohesive architecture [19].

The core objective of OSTIS is the universal unification of knowledge representation through standardized semantic models. By translating diverse data types ranging from electronic health records and genomic datasets to clinical guidelines and sensor-generated biomarkers



Figure 1. Formalized knowledge base fragment for intestinal atony disease.

into a common semantic format, OSTIS eliminates structural and terminological disparities that hinder interoperability. This unification facilitates the creation of a global OSTIS Ecosystem, a federated network where healthcare systems, analytical tools, and domain-specific applications interoperate via shared semantic protocols.

Key advantages include:

1) Semantic interoperability enables seamless data exchange between legacy systems, AI-driven diagnostic modules, and IoT-enabled wearable devices, addressing fragmentation in current healthcare infrastructures
2) OSTIS supports dynamic knowledge inference through logic-based semantic networks, allowing systems to adapt recommendations based on evolving patient states, comorbidities, and epidemiological trends.
3) By embedding clinical ontologies (e.g., SNOMED CT, ICD-11) and causal relationships into its semantic framework, OSTIS ensures traceability of AI-generated decisions, aligning with regulatory demands for explainable AI in medicine.
4) The reuse of preconfigured semantic components and collaborative knowledge engineering within the OSTIS Ecosystem reduces redundant development efforts, enabling rapid prototyping and deployment.

For personalized medical systems, OSTIS provides a structured methodology to harmonize patient-centric data streams with population-level health analytics. Its semantic architecture inherently supports ethical imperatives, such as bias mitigation through ontology-guided data sampling and privacy preservation via granular access control mechanisms defined at the semantic level. An



Figure 2. Gastrointestinal tract's diseases ontology fragment.

example of ontology fragment is shown in the figure 2 and represents gastrointestinal tract's diseases subsection. The adoption of OSTIS is posited to advance the realization of "4P" medicine (predictive, preventive, personalized, participatory) by fostering interoperable, context-sensitive healthcare ecosystems.

The system architecture comprises three core components: a knowledge base, a problem solver, and a web-based user interface. The knowledge base is structured as a semantic network of disease-specific modules containing granular symptom profiles, laboratory parameter correlations, and pathophysiological relationships. An

example of a formalized fragment of a knowledge base is shown in the figure 5. These modules are interconnected within a unified semantic memory, enabling rapid and precise knowledge processing through context-aware reasoning. Problem solver integrates logical inference rules with adaptive algorithms to execute diagnostic operations. The hematological diagnostic workflow follows a multi-stage pipeline:

1) Data ingestion, where acquisition of heterogeneous blood test parameters is made.
2) Data normalization, where conversion of raw values into ontology-compatible semantic representations is made.
3) Pattern recognition, where comparison of normalized data against reference ranges and disease-specific signatures within the knowledge base is made.
4) Conflict resolution, where reconciliation of ambiguous findings via probabilistic scoring and evidence-based decision matrices is made.
5) Output generation, where production of ranked diagnostic hypotheses annotated with confidence intervals and supporting biomarkers is made.

This architecture ensures clinician-centric operation, where the interface presents hypotheses as actionable recommendations requiring mandatory physician validation prior to treatment planning.

V. Blood-based biomarkers in disease diagnostics

Modern disease diagnostics are inconceivable without blood analysis – a method combining the precision of laboratory science with clinical interpretation. Blood serves as a universal indicator of health, reflecting organ dysfunction, metabolic disturbances, and latent pathological processes long before overt symptoms manifest. Over recent decades, technological advancements have transformed routine blood tests into robust tools of personalized medicine, enabling not only disease detection but also the prediction of disease progression.

Blood tests analyzing white blood cells (WBCs), platelets, and red blood cells (RBCs) are foundational for identifying a wide range of conditions, from infections to blood disorders. Each cell type provides unique insights into health and disease [20].

WBCs reflect the body's immune response. Elevated WBC counts (leukocytosis) often indicate bacterial infections, such as pneumonia, where neutrophils dominate. Viral infections, like mononucleosis, typically increase lymphocytes and may show atypical cells. Low WBC counts (leukopenia) can signal autoimmune diseases, chemotherapy effects, or bone marrow disorders. Abnormal cells, such as immature blasts, are critical for diagnosing leukemia. For example, chronic lymphocytic leukemia is identified by a high lymphocyte count and specific cell markers.

Platelet levels help assess clotting risks. High platelet counts (thrombocytosis) may occur in inflammatory diseases (e. g., rheumatoid arthritis) or blood cancers like essential thrombocythemia, linked to genetic mutations. Low platelet counts (thrombocytopenia) arise from immune destruction (e. g., immune thrombocytopenia), liver disease, or bone marrow failure. Severe thrombocytopenia raises bleeding risks.

RBCs and hemoglobin levels diagnose anemia and polycythemia. Anemia is classified by cell size:

- microcytic anemia (small cells) suggests iron deficiency, confirmed by low ferritin;
- macrocytic anemia (large cells) often stems from vitamin B12 or folate deficiency, detectable via blood tests;
- normocytic anemia (normal cell size) may indicate chronic diseases.

High RBC counts (polycythemia) can result from genetic conditions, lung diseases, or tumors overproducing erythropoietin. Hemolytic anemia, marked by rapid RBC breakdown, shows increased young RBCs (reticulocytes) and low haptoglobin.

Combined analysis of WBCs, platelets, and RBCs enhances diagnostic accuracy. For instance, low levels of all cells (pancytopenia) may indicate bone marrow failure or cancer spread. Elevated platelets with high RBCs suggest blood cancers, requiring genetic testing (Tefferi et al., 2020). Blood smear microscopy identifies cell abnormalities, such as immature cells in leukemia or fragmented RBCs in hemolysis [21], [22].

Figure 2 illustrates the successful implementation of a diagnostic rule based on leukocyte, thrombocyte, and erythrocyte parameters in human blood, designed using the SCg (Semantic Code graphical) knowledge representation language.

Blood tests measuring thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) are pivotal for evaluating endocrine function, particularly in thyroid and reproductive health. These hormones, produced by the pituitary gland, serve as biomarkers for disorders ranging from hypothyroidism to infertility [23].

TSH regulates thyroid hormone production (thyroxine, T4, and triiodothyronine, T3). Elevated TSH (>4.0 mU/L) with low free T4 indicates primary hypothyroidism, often caused by autoimmune Hashimoto's thyroiditis or iodine deficiency. This reflects the pituitary's attempt to stimulate an underactive thyroid. Conversely, suppressed TSH (<0.4 mU/L) with high T4/T3 signals hyperthyroidism, commonly due to Graves' disease or toxic nodules. Subclinical hypothyroidism (TSH 4.0–10.0 mU/L with normal T4) may progress to overt disease, especially with anti-thyroid peroxidase antibodies.

FSH and LH govern reproductive function. In women, they regulate the menstrual cycle and ovarian activ-



Figure 3. Formalized blood test diagnostic rule for intestinal atony disease.

ity. Elevated FSH (>25 IU/L) and LH (>15 IU/L) in reproductive-aged women suggest primary ovarian insufficiency (POI), marked by follicular depletion. During menopause, sustained high FSH/LH confirms ovarian failure. Conversely, low FSH/LH indicates hypogonadotropic hypogonadism, often due to pituitary tumors, stress, or excessive exercise, impairing ovulation and estrogen production [24].

In polycystic ovary syndrome, an LH/FSH ratio >2:1 is common, driven by hypothalamic-pituitary dysregulation. This imbalance promotes androgen overproduction, contributing to irregular cycles and infertility.

In men, FSH stimulates sperm production, while LH triggers testosterone synthesis. Elevated FSH/LH with low testosterone indicates primary testicular failure (e.g., Klinefelter syndrome). Low FSH/LH with low testosterone points to secondary hypogonadism, often linked to pituitary disorders [25].

Formalized rules implemented in the SCg language, as exemplified in this section, are utilized by the developing intelligent personalized healthcare system, aiding in preliminary disease identification. Designed algorithm employs formalized rules to analyze user-provided blood parameters against reference values, evaluate marginal thresholds and conflicts, determine possible disease associations, and return a diagnostic result.

The proposed system is designed to primarily automate the diagnostic workflow associated with blood test analysis, thereby significantly alleviating the workload of healthcare personnel. It is critical to emphasize that the system functions as a decision-support tool, generating probabilistic diagnostic hypotheses based on algorithmic interpretation of hematological parameters. Final clinical decisions, particularly those involving life-critical interventions, remain the exclusive responsibility of licensed medical professionals. This human-centric design ensures adherence to ethical obligations in medical practice, preserving clinician oversight as a non-negotiable component of patient care.

The workflow of the proposed intelligent system is illustrated in Figure 3. A blood sample undergoes automated analysis, where key parameters including white blood cell count, platelet levels and red blood cell morphology are extracted and processed using algorithms. The system identifies anomalies and correlates them with knowledge base-stored reference data to generate ranked diagnostic hypotheses. These hypotheses are presented to the clinician via an interpretable interface. Crucially, the physician retains full authority to accept, modify, or reject the system's suggestions, ensuring ethical accountability.

VI. Conclusion

The convergence of blood-based biomarker diagnostics and intelligent semantic architecture represents a paradigm shift in modern healthcare systems. Building upon analysis of leukocyte, thrombocyte, and erythrocyte parameter modeling via SCg, this work extends the framework through Open Semantic Technology for Intelligent Systems, which unifies diagnostic rule formalization with context-aware reasoning. By harmonizing



Figure 4. Formalized blood test diagnostic rule for hypogonadotropic hypogonadism disease.



Figure 5. The workflow of the proposed intelligent system.

heterogeneous data streams from hematological indices to multimodal health records, OSTIS addresses critical challenges in interoperability, ethical governance, and explainable AI, while preserving patient-centric priorities. The proposed architecture synthesizes adaptive semantic interoperability protocols and regulatory-compliant design to advance 4P (predictive, preventive, personalized, participatory) medicine. Notably, the integration of domain-specific diagnostic logic (e. g., blood biomarker thresholds) with OSTIS's knowledge representation capabilities demonstrates a scalable pathway for translating computational innovations into clinical workflows.

References

[1] Topol E.J. High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine, 2019, Vol. 25, №. 1, P. 44–56.

[2] Shilo S. et al. Artificial intelligence in healthcare: an essential guide for leaders. Nature Medicine, 2020, Vol. 26, №. 1, P. 29–38.

[3] Liyanage H. et al. Semantic interoperability in healthcare: a systematic literature review. Journal of Biomedical Informatics, 2020, Vol. 108, №. 103500.
[4] Kumar A. et al. Adaptive machine learning for real-time decision support in critical care. NPJ Digital Medicine, 2020, Vol. 3, №. 1.
[5] Caruana R. et al. Intelligible models for healthcare: Predicting pneumonia risk and hospital 30-day readmission. Proceedings of the 21th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, 2015, Vol. 1, №. 1.
[6] Rieke N. et al. The future of digital health with federated learning. Nature Machine Intelligence, 2020, Vol. 2, №. 11.
[7] Holden R.J. et al. Human factors engineering and user-centered design for mobile health technology: Enhancing usability, adoption, and clinical outcomes. Journal of the American Medical Informatics Association, 2013, Vol. 20, №. 4.
[8] Ghassemi M. et al. The ethical algorithm: Addressing bias in machine learning for healthcare. Nature Medicine, 2021, Vol. 27, №. 1.
[9] Vayena E. et al. Machine learning in medicine: Addressing ethical challenges. Nature Biotechnology, 2018, Vol. 36, №. 5.
[10] Kankanhalli A. et al. Scaling digital health innovations in resource-limited settings: Challenges and strategies. The Lancet Digital Health, 2022, Vol. 4, №. 5.
[11] European Union. General Data Protection Regulation (GDPR). Official Journal of the European Union, 2018, Vol. 59, №. 1, P. 1–88.
[12] U.S. Congress. Health Insurance Portability and Accountability Act (HIPAA). United States Statutes at Large, 1996, Vol. 110, №. 1, P. 1936–2103.
[13] National People's Congress of China. Personal Information Protection Law (PIPL). Gazette of the Standing Committee of the National People's Congress, 2021, Vol. 43, №. 8.
[14] World Health Organization. Ethics and governance of artificial intelligence for health. WHO Guidance, 2021, Vol. 1, №. 1, P. 1–132.
[15] Adamson A.S. et al. Diagnostic disparities in dermatology AI: A meta-analysis. Nature Medicine, 2022, Vol. 28, №. 1, P. 1–9.
[16] Global Alliance for Genomics and Health. Beacon Project: Global genomic data sharing. GA4GH Technical Reports, 2022, Vol. 4, №. 3.
[17] UNESCO. Recommendation on the Ethics of Artificial Intelligence. UNESCO Publications, 2021, Vol. 1, №. 1, P. 1–28.
[18] Medicines and Healthcare products Regulatory Agency (MHRA). AI as a Medical Device: Roadmap 2023. MHRA Policy Documents, 2023, Vol. 1, №. 1.
[19] Golenkov V. V., Guliakina N. A., Shunkevich D. V. Open Semantic Technology for Intelligent Systems, 2013, P. 690
[20] Kratz A. et al. Laboratory identification of infectious diseases: a guide for utilization. Clinical Chemistry and Laboratory Medicine, 2004, Vol. 42, №. 3, P. 280–291.
[21] Arber D.A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 2016, Vol. 127, №. 20, P. 2391–2405.
[22] Neunert C. et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances, 2019, Vol. 3, №. 23, P. 3829–3866.
[23] Chaker L. et al. Hypothyroidism. The Lancet, 2017, Vol. 390, №. 10101, P. 1550–1562.
[24] Santoro N. et al. Menopause and the menopausal transition. Endotext, 2016.
[25] Bhasin S. et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 2018, Vol. 103, №. 5, P. 1715–1744.

ПРИНЦИПЫ ПРОЕКТИРОВАНИЯ ИНТЕЛЛЕКТУАЛЬНЫХ СИСТЕМ ПЕРСОНАЛЬНОГО МЕДИЦИНСКОГО ОБСЛУЖИВАНИЯ

Сальников Д. А.

Данная статья предлагает подход для проектирования современных интеллектуальных систем персонального медицинского обслуживания, нацеленный на синергию технологических инноваций и клинической применимости. В работе описаны архитектурные решения, методы интеграции знаний, модели этического регулирования и парадигмы взаимодействия человека с интеллектуальной системой, необходимые для создания масштабируемых, безопасных и социально приемлемых систем. Путем изучения междисциплинарных подходов на стыке компьютерных наук, клинической медицины и биоэтики исследование направлено на преодоление разрыва между теоретическими разработками и практическим внедрением в клинические процессы.

Received 25.03.2025